vs

Side-by-side financial comparison of GEN Restaurant Group, Inc. (GENK) and Orchestra BioMed Holdings, Inc. (OBIO). Click either name above to swap in a different company.

GEN Restaurant Group, Inc. is the larger business by last-quarter revenue ($49.7M vs $30.9M, roughly 1.6× Orchestra BioMed Holdings, Inc.). Orchestra BioMed Holdings, Inc. runs the higher net margin — 20.2% vs -3.8%, a 24.0% gap on every dollar of revenue. On growth, Orchestra BioMed Holdings, Inc. posted the faster year-over-year revenue change (12120.2% vs -9.0%). Orchestra BioMed Holdings, Inc. produced more free cash flow last quarter ($-2.3M vs $-5.6M).

Gen Korean BBQ is an American chain of all-you-can-eat Korean barbecue restaurants mainly concentrated around the Western U.S. It opened in 2011, and has since grown to 43 locations as of 2024.

Orchestra BioMed Holdings, Inc. is a clinical-stage medical technology company focused on developing novel, evidence-based therapeutic solutions for cardiovascular and other high-burden chronic diseases. It collaborates with leading healthcare stakeholders, operates primarily across North American and European markets, with core segments covering interventional cardiology and chronic disease care optimization.

GENK vs OBIO — Head-to-Head

Bigger by revenue
GENK
GENK
1.6× larger
GENK
$49.7M
$30.9M
OBIO
Growing faster (revenue YoY)
OBIO
OBIO
+12129.1% gap
OBIO
12120.2%
-9.0%
GENK
Higher net margin
OBIO
OBIO
24.0% more per $
OBIO
20.2%
-3.8%
GENK
More free cash flow
OBIO
OBIO
$3.3M more FCF
OBIO
$-2.3M
$-5.6M
GENK

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
GENK
GENK
OBIO
OBIO
Revenue
$49.7M
$30.9M
Net Profit
$-1.9M
$6.2M
Gross Margin
99.8%
Operating Margin
-24.5%
21.8%
Net Margin
-3.8%
20.2%
Revenue YoY
-9.0%
12120.2%
Net Profit YoY
-821.4%
138.7%
EPS (diluted)
$-0.37
$0.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GENK
GENK
OBIO
OBIO
Q4 25
$49.7M
$30.9M
Q3 25
$50.4M
Q2 25
$55.0M
Q1 25
$57.3M
Q4 24
$54.7M
Q3 24
$49.1M
Q2 24
$53.9M
Q1 24
$50.8M
Net Profit
GENK
GENK
OBIO
OBIO
Q4 25
$-1.9M
$6.2M
Q3 25
$-566.0K
Q2 25
$-261.0K
Q1 25
$-301.0K
Q4 24
$-206.0K
Q3 24
$25.0K
Q2 24
$277.0K
Q1 24
$496.0K
Gross Margin
GENK
GENK
OBIO
OBIO
Q4 25
99.8%
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Operating Margin
GENK
GENK
OBIO
OBIO
Q4 25
-24.5%
21.8%
Q3 25
-7.4%
Q2 25
-3.4%
Q1 25
-3.8%
Q4 24
-2.4%
Q3 24
0.2%
Q2 24
3.0%
Q1 24
0.2%
Net Margin
GENK
GENK
OBIO
OBIO
Q4 25
-3.8%
20.2%
Q3 25
-1.1%
Q2 25
-0.5%
Q1 25
-0.5%
Q4 24
-0.4%
Q3 24
0.1%
Q2 24
0.5%
Q1 24
1.0%
EPS (diluted)
GENK
GENK
OBIO
OBIO
Q4 25
$-0.37
$0.28
Q3 25
$-0.11
Q2 25
$-0.05
Q1 25
$-0.06
Q4 24
$-0.05
Q3 24
$0.01
Q2 24
$0.06
Q1 24
$0.11

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GENK
GENK
OBIO
OBIO
Cash + ST InvestmentsLiquidity on hand
$2.8M
$106.5M
Total DebtLower is stronger
$13.6M
$15.0M
Stockholders' EquityBook value
$26.5M
$53.6M
Total Assets
$259.9M
$114.9M
Debt / EquityLower = less leverage
0.51×
0.28×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GENK
GENK
OBIO
OBIO
Q4 25
$2.8M
$106.5M
Q3 25
$4.8M
Q2 25
$9.6M
Q1 25
$15.4M
Q4 24
$23.7M
Q3 24
$22.1M
Q2 24
$29.2M
Q1 24
$28.1M
Total Debt
GENK
GENK
OBIO
OBIO
Q4 25
$13.6M
$15.0M
Q3 25
$10.8M
Q2 25
$7.8M
Q1 25
$6.5M
Q4 24
$6.9M
Q3 24
$7.2M
Q2 24
$7.6M
Q1 24
$7.7M
Stockholders' Equity
GENK
GENK
OBIO
OBIO
Q4 25
$26.5M
$53.6M
Q3 25
$38.1M
Q2 25
$41.0M
Q1 25
$42.8M
Q4 24
$44.1M
Q3 24
$46.5M
Q2 24
$45.9M
Q1 24
$40.4M
Total Assets
GENK
GENK
OBIO
OBIO
Q4 25
$259.9M
$114.9M
Q3 25
$245.5M
Q2 25
$246.3M
Q1 25
$232.4M
Q4 24
$240.4M
Q3 24
$225.7M
Q2 24
$218.8M
Q1 24
$214.5M
Debt / Equity
GENK
GENK
OBIO
OBIO
Q4 25
0.51×
0.28×
Q3 25
0.28×
Q2 25
0.19×
Q1 25
0.15×
Q4 24
0.16×
Q3 24
0.16×
Q2 24
0.17×
Q1 24
0.19×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GENK
GENK
OBIO
OBIO
Operating Cash FlowLast quarter
$-426.0K
$-2.3M
Free Cash FlowOCF − Capex
$-5.6M
$-2.3M
FCF MarginFCF / Revenue
-11.3%
-7.4%
Capex IntensityCapex / Revenue
10.5%
0.1%
Cash ConversionOCF / Net Profit
-0.36×
TTM Free Cash FlowTrailing 4 quarters
$-24.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GENK
GENK
OBIO
OBIO
Q4 25
$-426.0K
$-2.3M
Q3 25
$-1.6M
Q2 25
$3.3M
Q1 25
$2.2M
Q4 24
$7.3M
Q3 24
$1.4M
Q2 24
$5.6M
Q1 24
$3.5M
Free Cash Flow
GENK
GENK
OBIO
OBIO
Q4 25
$-5.6M
$-2.3M
Q3 25
$-7.7M
Q2 25
$-6.3M
Q1 25
$-4.7M
Q4 24
$165.0K
Q3 24
$-6.8M
Q2 24
$1.2M
Q1 24
$-586.0K
FCF Margin
GENK
GENK
OBIO
OBIO
Q4 25
-11.3%
-7.4%
Q3 25
-15.3%
Q2 25
-11.5%
Q1 25
-8.2%
Q4 24
0.3%
Q3 24
-13.9%
Q2 24
2.3%
Q1 24
-1.2%
Capex Intensity
GENK
GENK
OBIO
OBIO
Q4 25
10.5%
0.1%
Q3 25
12.0%
Q2 25
17.5%
Q1 25
11.9%
Q4 24
13.1%
Q3 24
16.9%
Q2 24
8.0%
Q1 24
8.1%
Cash Conversion
GENK
GENK
OBIO
OBIO
Q4 25
-0.36×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
57.96×
Q2 24
20.06×
Q1 24
7.08×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons